CD274 and liver cancer: Additionally, although combination modalities involving in CAF-targeting and anti-PD-L1 drugs deemed effective in other cancers, it is crucial to investigate whether or not CAF-directed agents can overcome anti-PD-L1 resistance and yield clinical benefits in patients with liver cancer.